R R

What Is Ngenla?

Ngenla is a prescription growth hormone medication containing somatrogon-ghla, a long-acting human growth hormone analog. It is approved for children aged three years and older who have growth failure caused by inadequate natural growth hormone production. Ngenla is administered as a subcutaneous injection once weekly. Treatment is supervised by a healthcare professional experienced in pediatric growth hormone deficiency and requires regular monitoring of growth and potential side effects.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Ngenla?

Ngenla is a prescription growth hormone medication containing somatrogon-ghla, a long-acting human growth hormone analog. It is approved for children aged three years and older who have growth failure caused by inadequate natural growth hormone production. Ngenla is administered as a subcutaneous injection once weekly. Treatment is supervised by a healthcare professional experienced in pediatric growth hormone deficiency and requires regular monitoring of growth and potential side effects.

read more about ngenla ...

Copy this HTML:

Copy HTML Copied!

How Does Ngenla Work?

Ngenla contains somatrogon-ghla, which activates growth hormone receptors and stimulates processes involved in normal childhood growth. It promotes the production of insulin-like growth factor 1 (IGF-1), a hormone that supports bone and tissue development. Its molecular structure extends its activity, making once-weekly administration possible. Ngenla replaces insufficient growth hormone activity but does not treat every cause of short stature or growth delay.

Who Is Eligible for Ngenla Treatment?

Ngenla is prescribed to pediatric patients aged three years and older with confirmed growth hormone deficiency that causes growth failure. An endocrinologist evaluates growth patterns, medical history, laboratory findings, and other possible causes of reduced growth before starting treatment. Ngenla should not be used in patients with active malignancy, acute critical illness, or closed growth plates. It is not indicated for growth failure associated with genetically confirmed Prader-Willi syndrome.

How Is Ngenla Administered?

Ngenla is injected beneath the skin once weekly using a prefilled pen. The recommended starting dose is 0.66 mg per kilogram of body weight per week, adjusted according to growth response and clinical assessment. Injections can be given in the abdomen, thighs, buttocks, or upper arms, with sites rotated regularly. A missed dose can be administered within three days of the scheduled date. After that interval, the missed dose should be skipped and the regular schedule resumed.

What Are the Side Effects and Warnings of Ngenla?

Common side effects include injection-site reactions, headache, fever, cough, and gastrointestinal discomfort. Serious concerns include increased intracranial pressure, changes in blood sugar, thyroid dysfunction, and worsening scoliosis. Growth hormone treatment can also contribute to slipped capital femoral epiphysis, which can cause limping or hip and knee pain. Patients require monitoring for visual changes, persistent headaches, and other complications. Ngenla should not be used in patients with active cancer.

Common Questions About Ngenla

What is Ngenla used for?

Ngenla treats growth failure caused by growth hormone deficiency in children aged three years and older. It is prescribed after appropriate medical evaluation.

How often is Ngenla injected?

Ngenla is administered once weekly as a subcutaneous injection. The dose is based on body weight and adjusted according to the child's growth response.

Is Ngenla the same as human growth hormone?

Ngenla contains somatrogon-ghla, a long-acting analog of human growth hormone. It acts on growth hormone receptors but has a longer dosing interval than daily somatropin products.

Can Ngenla affect vision?

Growth hormone treatment can cause increased intracranial pressure accompanied by headaches or visual changes. Eye examinations are recommended before treatment and periodically afterward.

References

DailyMed - NGENLA (somatrogon-ghla) injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dce529-b741-4a1b-8842-3ad77be6e308. Date Accessed October 19, 2026.

Drug Trials Snapshots: NGENLA. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-ngenla. Date Accessed October 19, 2026.

NGENLA (somatrogon-ghla) Prescribing Information. Pfizer. https://labeling.pfizer.com/ShowLabeling.aspx?id=19642. Date Accessed October 19, 2026.

Ngenla. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/ngenla. Date Accessed October 19, 2026.

Somatrogon-ghla Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a623041.html. Date Accessed October 19, 2026.